No Data
Evogene Says Corteva Terminates Licensing Agreement of Lavie Bio Subsidiary
Express News | Evogene Ltd: Unit Receives Notice of Termination of Licensing Agreement With Corteva for Bio Fungicide Lead Candidates
Evogene Price Target Lowered to $5 From $12 at Lake Street
Lake Street Maintains Evogene(EVGN.US) With Buy Rating, Cuts Target Price to $5
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
LooseSpeculator : This is EVGN's subsidiary, Lavie. An agreement was terminated but the one time payment Lavie received upon signing the agreement does NOT have to be returned, and Lavie regains all rights to their licensed technology.